Literature DB >> 21080190

The role of the long-duration response to levodopa in Parkinson's disease.

Mario Zappia1, Alessandra Nicoletti.   

Abstract

The long-duration response (LDR) to levodopa is an important component of the therapeutic response to the drug in Parkinson's disease (PD). Some characteristics are peculiar: it is independent from peripheral pharmacokinetics of levodopa, but it is dependent on the intervals between doses and on the size of each dose. Once the LDR fully develops, it is stable and maximal. After stopping treatment, the decay rate is inversely related to the severity of PD; when the LDR decreases over time, the patients present a fluctuating motor response. Therapeutic strategies based on the development and maintenance of the LDR should be sought to maximize the clinical benefit induced by levodopa and to avoid the appearance of motor complications.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21080190     DOI: 10.1007/s00415-010-5731-0

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  17 in total

1.  The long-duration response to L-dopa in the treatment of early PD.

Authors:  M Zappia; R L Oliveri; D Bosco; G Nicoletti; D Branca; M Caracciolo; I D Napoli; A Gambardella; A Quattrone
Journal:  Neurology       Date:  2000-05-23       Impact factor: 9.910

2.  Apomorphine can sustain the long-duration response to L-DOPA in fluctuating PD.

Authors:  J G Nutt; J H Carter
Journal:  Neurology       Date:  2000-01-11       Impact factor: 9.910

3.  Long-duration response to levodopa.

Authors:  J G Nutt; J H Carter; W R Woodward
Journal:  Neurology       Date:  1995-08       Impact factor: 9.910

4.  Short- and long-duration responses to levodopa during the first year of levodopa therapy.

Authors:  J G Nutt; J H Carter; L Van Houten; W R Woodward
Journal:  Ann Neurol       Date:  1997-09       Impact factor: 10.422

5.  Long-duration response to levodopa influences the pharmacodynamics of short-duration response in Parkinson's disease.

Authors:  M Zappia; R Colao; R Montesanti; M Rizzo; U Aguglia; A Gambardella; R L Oliveri; A Quattrone
Journal:  Ann Neurol       Date:  1997-08       Impact factor: 10.422

6.  The long-duration action of levodopa may be due to a postsynaptic effect.

Authors:  L Barbato; F Stocchi; A Monge; L Vacca; S Ruggieri; G Nordera; C D Marsden
Journal:  Clin Neuropharmacol       Date:  1997-10       Impact factor: 1.592

7.  Oral pulse levodopa therapy in mild Parkinson's disease.

Authors:  A Quattrone; M Zappia
Journal:  Neurology       Date:  1993-06       Impact factor: 9.910

8.  The subacute levodopa test for evaluating long-duration response in Parkinson's disease.

Authors:  A Quattrone; M Zappia; U Aguglia; D Branca; R Colao; R Montesanti; G Nicoletti; A Palmieri; G Parlato; M Rizzo
Journal:  Ann Neurol       Date:  1995-09       Impact factor: 10.422

9.  Usefulness of movement time in the assessment of Parkinson's disease.

Authors:  M Zappia; R Montesanti; R Colao; A Quattrone
Journal:  J Neurol       Date:  1994-08       Impact factor: 4.849

10.  Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenon.

Authors:  J G Nutt; W R Woodward; J H Carter; S T Gancher
Journal:  Arch Neurol       Date:  1992-11
View more
  2 in total

Review 1.  The missing, the short, and the long: Levodopa responses and dopamine actions.

Authors:  Roger L Albin; Daniel K Leventhal
Journal:  Ann Neurol       Date:  2017-06-05       Impact factor: 10.422

Review 2.  The role of neuroplasticity in dopaminergic therapy for Parkinson disease.

Authors:  Xiaoxi Zhuang; Pietro Mazzoni; Un Jung Kang
Journal:  Nat Rev Neurol       Date:  2013-04-16       Impact factor: 42.937

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.